RxDoctor Payments Data

Kathleen Grissett, MD

Psychiatry · Orange Park, FLNPI 1821170085

Payments from drug & device makers

$17,504in general payments, 2019–2025

Across 1,081 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Otsuka America Pharmaceutical, Inc.$2K
  • Sunovion Pharmaceuticals Inc.$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Supernus Pharmaceuticals, Inc.$1K
  • Alkermes, Inc.$837
  • plus $8K from 34 others

What the payments were for

  • Food & beverage$17,38199%
  • Education$1241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,504 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$43,766
Medicare patients
75
Services billed
500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl17$27,347
NuedextaDextromethorphan Hbr/Quinidine13$20,339
RexultiBrexpiprazole12$20,109
TrintellixVortioxetine Hydrobromide13$10,336
Chlorpromazine Hcl26$3,486
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine54$3,004
Bupropion XlBupropion Hcl61$2,839
Naltrexone Hcl15$2,148
Olanzapine39$1,692
Carbamazepine14$1,367
Desvenlafaxine Succinate ErDesvenlafaxine Succinate25$1,244
Aripiprazole27$1,178
Buspirone Hcl38$1,140
Trazodone Hcl81$947
Quetiapine Fumarate51$890

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$2,873$27,34717 claims
Avanir Pharmaceuticals, Inc.Nuedexta$372$20,33913 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,696$20,10912 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$1,554$10,33613 claims
Lilly USA, LLCOlanzapine$16$1,69239 claims
Almatica Pharma LLCSertraline Hcl$254$6923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Orange Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →